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Abstract
Despite progress in the diagnosis, prevention and therapy for
hospital-acquired infections, ventilator-associated pneumonia
(VAP) continues to complicate the course of a significant
proportion of patients receiving mechanical ventilation. Mortality
rates among patients with VAP have been reported to be as high
as 72%, and the morbidity associated with VAP is also
considerable, adding days to the hospital stay and increasing
health care costs. Appropriate initial antimicrobial therapy for
patients with VAP has been shown to reduce mortality rates and
improve outcomes; therefore, rapid identification of infected
patients and timely, accurate selection of effective antimicrobial
agents are important clinical goals. The primary organisms
responsible for VAP include Enterobacteriaceae, Pseudomonas
aeruginosa and  Staphylococcus aureus. However, aetiologies
differ considerably between intensive care units, and the increase
in antibiotic resistance and nosocomial outbreaks worldwide have
presented clinicians with a serious dilemma with respect to
selecting appropriate empirical therapy. To date, no optimal
antimicrobial regimen for the treatment of VAP has been identified,
largely because none of the currently marketed antibiotics has a
sufficiently extended spectrum of activity to cover all of the
potential key pathogens. More active, less toxic antibacterial
agents are still needed, in particular to combat problematic
pathogens such as multiresistant Gram-negative bacilli and
resistant Gram-positive organisms (e.g. methicillin-resistant S
aureus).
Introduction
Pneumonia is the single most common nosocomial infection
among patients in intensive care units (ICUs) [1,2]. Rates of
pneumonia are considerably higher among patients
hospitalized in ICUs than in hospital wards, and the risk for
developing pneumonia is 3-fold to 10-fold higher for
intubated patients receiving mechanical ventilation [1,2]. Of
hospital-acquired infections, nosocomial pneumonia is
reported to be the leading cause of death, being responsible
for half of the hospital-acquired infections that result in death
[3,4]. However, whether patients with ventilator-associated
pneumonia (VAP) have associated mortality is controversial.
Indeed, in a large matched cohort study of patients with early
onset VAP [5], an association between VAP and poor clinical
and economic outcomes was demonstrated, but hospital
mortality was not attributable to VAP in this analysis. On the
other hand, there does appear to be a correlation between
severity of illness at admission and survival [6]. Reported
mortality in VAP patients ranges from 33% to 72% [4], with
the upper range reflecting the increased risk for mortality
among the elderly, patients with impaired cardiopulmonary
function, immunocompromised patients, patients who require
prolonged intubation, and those at risk for infection with
Pseudomonas aeruginosa or methicillin-resistant Staphylo-
coccus aureus (MRSA) [7].
Fiel [7] recently showed that a twofold reduction in mortality
could be achieved in patients with nosocomial pneumonia
with prompt use of appropriate antibiotics, but what are the
appropriate therapeutic options for VAP, which is often a
polymicrobial infection [8]? The published literature indicates
that Gram-negative bacteria account for between 55% and
85% of cases of nosocomial pneumonia [8] but that the
Gram-positive pathogen S aureus is the second most
prevalent organism, accounting for 10–20% of all nosocomial
pneumonias. Moreover, the growing incidence of methicillin-
resistant strains of S aureus has important implications for
the design of treatment regimens. Clearly, an agent, or
agents, with broad-spectrum activity against both Gram-
positive and Gram-negative pathogens is needed for optimal
management of these infections. In this review we examine
the incidence, aetiology and diagnosis of VAP, and address
current therapeutic options.
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Pathophysiology
There are several factors that potentially contribute to the
high rates of VAP in hospitalized patients. First, hospitals
contain clusters of highly vulnerable patients, many of whom
will have predisposing pulmonary conditions that compromise
defence mechanisms in their airways. Although the
respiratory tract is designed to prevent the entry of
pathogenic organisms into the lungs and to eradicate such
pathogens should they bypass the upper airway host
defences, these defence mechanisms can be overwhelmed
by, for example, a large aspirated inoculum or an inherently
virulent organism.
Second, the most common means of acquiring pneumonia is
via aspiration [9]. Aspiration is promoted by supine position
and by upper airway and gastrointestinal intubation;
aspiration in mechanically ventilated patients occurs around
the outside of the endotracheal tube rather than through the
lumen. Leakage around the endotracheal cuff can be
demonstrated in most patients. Given that as many as 45% of
healthy individuals aspirate during sleep, it is not surprising
that aspiration is even more common among patients with
abnormal swallowing, impaired gag reflexes, compromised
consciousness due to medication or anaesthesia, delayed
gastric emptying, or decreased gastric motility.
Third, the dominant organisms in nosocomial pneumonia are
aerobic Gram-negative bacilli [10–12]. These bacteria
presumably reach the lower airway via aspiration of gastric
contents or of upper airway secretions. Oropharyngeal
colonization with Gram-negative bacilli is unusual in otherwise
healthy, nonhospitalized individuals. In moderately ill patients,
however, the carriage rate is around 16%, rising to almost
75% in severely ill patients [13]. Thus, the propensity for
colonization of the upper airways directly correlates with
severity of illness. In addition to severity of illness, several
other factors have been identified as being associated with
Gram-negative oropharyngeal colonization, as shown in
Table 1. Other means by which pneumonia can be acquired
include aspiration from the stomach or nose and paranasal
sinuses. Aspiration of gastric contents can be minimized by
maintaining the patient in a semi-recumbent position, but this
is not an effective measure for minimizing oropharyngeal
aspiration.
Incidence
The reported frequencies of VAP vary from 8% to 28%. In the
National Nosocomial Infections Surveillance system [14],
rates of VAP range from five cases per 1000 ventilator days
in paediatric patients to 16 cases per 1000 ventilator days in
patients with thermal injury or trauma. Kollef [15] reported an
incidence of 22% among cardiothoracic patients, as
compared with 14% among other surgical patients and 9.3%
in medical patients, demonstrating that rates of VAP are
generally higher among surgical than among medical
patients.
Although nosocomial pneumonia accounts for only about
15% of hospital-acquired infections, it is the most frequent
lethal nosocomial infection [2,16]. Mortality rates for
nosocomial pneumonia are reported to range from 20% to
71%, whereas mortality rates for nosocomial pneumonia
acquired in the ICU range from 20% to 40% [2,16]. The main
risk factors for mortality among patients with nosocomial
pneumonia include severity of underlying illness,
inappropriate antibiotic therapy, advanced age, and infection
with a high-risk pathogen such as P aeruginosa.
Each episode of nosocomial pneumonia will prolong a
hospital stay by 7–9 days, resulting in increased hospital
costs. In a study conducted by Rello and coworkers [5] in
which patients with VAP were matched to 2243 control
individuals without VAP, the patients with VAP had a
significantly longer duration of mechanical ventilation
(14.3 ± 15.5 days versus 4.7 ± 7.0 days; P < 0.001), ICU
stay (11.7 ± 11.0 days versus 5.6 ± 6.1 days; P < 0.001),
and hospital stay (25.5 ± 22.8 days versus 14.0 ± 14.6 days;
P < 0.001). In addition, VAP in these patients was associated
with increased hospital costs in excess of US$40,000 per
patient (104,983 ± 91,080 versus 63,689 ± 75,030 [in
US$]; P < 0.001).
Ibrahim and coworkers [11] found that hospital mortality was
significantly greater in patients with early-onset nosocomial
pneumonia (which they defined as occurring within 96 hours
of ICU admission) and late-onset nosocomial pneumonia
(defined as occurring after 96 hours of ICU admission) than
in ICU patients who did not develop pneumonia. This
indicates that both early-onset and late-onset pneumonia are
associated with increased hospital mortality rates and length
of stay. Ibrahim and coworkers also found that prior
hospitalization and antibiotic use probably contributes to
development of early-onset pneumonia due to MRSA and
other resistant organisms. However, typically, antibiotics can
help to prevent early-onset VAP and have a stronger
association with late-onset disease [17].
Table 1
Risk factors for oropharyngeal colonization by Gram-negative
bacilli
Life-threatening illness Pulmonary disease
Prolonged hospitalization/ Smoking
intensive care unit stay
Advanced age Uraemia
Antibiotic exposure Alcoholism
Intubation Coma
Major surgery Multiple organ failure
Malnutrition Neutropenia261
Aetiology
The dominant organisms in nosocomial pneumonia are
aerobic Gram-negative bacilli. Several studies have reported
that more than 60% of VAP is caused by aerobic Gram-
negative bacilli [18,19]. The predominant Gram-negative
bacilli that cause VAP are P aeruginosa, Acinetobacter spp.,
Proteus spp.,  Escherichia coli,  Klebsiella spp. and
Haemophilus spp. More recently, however, studies have
highlighted an increased prevalence of Gram-positive
organisms in this setting, with S aureus being the predominant
Gram-positive isolate (Table 2). For example, S aureus was
responsible for most episodes of nosocomial pneumonia in
the EPIC (European Prevalence of Infection in Intensive Care)
study [19], accounting 31% of the 836 cases in which
pathogens were identified. Anaerobic bacteria may be found
in 20–30% of cases, but they are not generally isolated when
using standard diagnostic specimen sources. When they are
found it is usually as part of a polymicrobial infection including
Gram-negative bacilli or S aureus, and their role is unclear
[16].  Legionella accounts for approximately 4% of all
nosocomial infections, based on a multihospital autopsy study
of patients with lethal nosocomial pneumonia. Large outbreaks
of Legionnaires’ disease in hospitals are generally associated
with contaminated water supplies that are distributed via air
conditioning systems or showerheads [20].
There is significant variability in aetiology between hospitals,
as shown in Fig. 1, which shows the different aetiologic
patterns for multiresistant pathogens in different institutions
among patients who were mechanically ventilated for more
than 7 days and had prior antibiotic exposure. Similarly, in a
study conducted by Valles and coworkers [21] in patients
with hospital-acquired pneumonia requiring ICU admission,
significant variations in aetiology were observed between
hospitals, particularly affecting the incidence of pneumonias
caused by Aspergillus spp. and Legionella pneumophila. This
study highlights the need for good local epidemiologic data
as part of effective therapeutic decision making.
Underlying disease may predispose patients to infection
with specific organisms. For example, patients with chronic
obstructive pulmonary disease are at increased risk for H
influenzae,  Moraxella catarrhalis, or Streptococcus
pneumoniae infections; cystic fibrosis increases the risk of
P aeruginosa and  S aureus infections; and trauma and
neurologic patients are at increased risk for S aureus
infection [16,22].
The time of onset of VAP also appears to correlate with
certain pathogens [12,16]. Early-onset VAP, defined as
occurring during the first 4 days of mechanical ventilation, is
often associated with high rates of S pneumoniae,  H
influenzae, methicillin-sensitive S aureus and susceptible
Enterobacteriaceae. Many of these pneumonias probably
reflect infection that was incubating in the community and
presented early during hospitalization. Late-onset VAP,
defined as developing 5 or more days after initiation of
mechanical ventilation, is more frequently caused by enteric
Gram-negative organisms, including P aeruginosa, Acineto-
bacter or Enterobacter spp., or by MRSA [12,16].
The rise in the number of multidrug-resistant pathogens in
recent years has led to the development of infections that are
difficult to treat and have limited physicians’ treatment
options. In particular, MRSA is now responsible for a
significant proportion of nosocomial pneumonias, and MRSA
strains with reduced susceptibility to vancomycin (glyco-
peptide-intermediate  S aureus) are causing concern.
Glycopeptide-intermediate  S aureus has been identified in
Japan, the USA and Europe [23]. In addition, glycopeptides
are suboptimal (50% overall mortality rate) as therapy for
MRSA pneumonia [24–27]. The incidence of multiresistant
pathogens is linked to local factors and varies from institution
to institution. Clinicians must therefore be aware of the
common organisms associated with both early-onset and
late-onset VAP in their own hospitals if they are to avoid
administering inappropriate initial therapy. In addition, ICUs
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Table 2
Common causative pathogens associated with ventilator-associated pneumonia
Frequency [n (%)]
Pathogen Trouillet [12] (n = 245) Rello [10,51] (n = 301) Ibrahim [11] (n = 420)
Pseudomonas aeruginosa 39 (15.9) 102 (33.9) 130 (30.9)
Acinetobacter baumannii 22 (9.0) 38 (12.6) 16 (3.8)
Haemophilus influenzae 15 (6.1) 26 (8.6) 19 (4.5)
Streptococcus pneumoniae 3 (1.2) 25 (8.3) 6 (1.4)
MRSA 20 (8.2) 10 (3.3) 81 (19.3)
MSSA 32 (13.1) 38 (12.6) 62 (14.7)
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.262
must collect epidemiologic data and be vigilant with respect
to local susceptibility patterns.
Diagnosis
Diagnosis of bacterial pneumonia in severely ill, mechanically
ventilated patients remains difficult for the clinician. The
criteria used most often for clinical diagnosis of nosocomial
pneumonia are fever, with a temperature >100.4°F (38°C);
leucocytosis or leucopenia; a new or increasing pulmonary
infiltrate on chest film; purulent tracheobronchial secretions;
and a sputum Gram stain with many polymorphonuclear
leucocytes, fewer than 10 epithelial cells, and a predominant
pathogen. VAP is pneumonia in persons in whom a device
was used to assist or control respiration continuously through
a tracheostomy or by endotracheal intubation within the
48 hours period before the onset of infection. Incidence
should be reported as days/1000 ventilation days [16,28].
However, this clinical picture can often be confused with a
variety of other infections and noninfectious pulmonary
processes in the ventilated ICU patient [28].
Radiographical evidence of pneumonia in ventilated patients
is also notoriously inaccurate. In a study of autopsy proven
VAP, Wunderink and coworkers [29] found that only air
bronchograms correlated with pneumonia in the total study
population and that no specific roentgenographic sign
correlated with pneumonia in patients with adult respiratory
distress syndrome. The diagnoses most frequently confused
with nosocomial pneumonia, based on radiographical
appearance, include adult respiratory distress syndrome,
congestive heart failure, atelectasis, pulmonary embolism and
neoplastic infiltration [28].
The use of lung tissue for diagnosis of pneumonia is not
recommended in most ventilated patients, although it can be
useful in some immunocompromised patients. Several
autopsy studies that compared clinical diagnosis with
histopathologic examinations identified errors in diagnosis
and treatment of pneumonia in 29–38% of patients [30,31].
In a study conducted by Fagon and coworkers [32] that
compared clinical diagnosis with histopathologic and broncho-
scopic bacteriologic criteria in ventilated patients, the clinical
diagnosis was correct in 62% of cases and therapeutic
treatment plan was appropriate in only 33% of cases.
Given the difficulty in diagnosing pneumonia in the ventilated
patient clinically, alternative methods of diagnosis have been
sought. Although simple qualitative culture of endotracheal
aspirates is a technique with a high percentage of false-
positive results due to bacterial colonization of the proximal
airways observed in most patients in the ICU, some studies
using quantitative culture techniques suggest that endo-
tracheal aspirate cultures may have an acceptable overall
diagnostic accuracy, similar to that with several other, more
invasive techniques [28]. Although quantitative endotracheal
aspirate cultures can correctly identify patients with
pneumonia, it should be borne in mind that the microbiologic
results cannot be used to infer which micro-organisms
present in the trachea are really present in the lungs.
Blind and bronchoscopic sampling of lower airways has also
been studied extensively. Fibreoptic bronchoscopy permits
direct access to the lower airways for sampling bronchial and
parenchymal tissues at the site of lung inflammation [28]. To
reach the bronchial tree, however, the bronchoscope must
traverse the endotracheal tube and proximal airways, where
contamination is likely to occur. Therefore, distal secretions
directly aspirated through the bronchoscope suction channel
are frequently contaminated, limiting their clinical specificity
[28]. Nevertheless, the use of invasive techniques such as
fibreoptic bronchoscopy, together with quantitative cultures
of bronchoscopic samples obtained with bronchoalveolar
lavage or protected specimen brush, can help to guide the
choice of antibiotic therapy and confirm the diagnosis of VAP.
What is clear is that avoiding delay in sampling and initiating
therapy quickly are more important than the type of
quantitative technique used.
Treatment strategy and impact of appropriate
antibiotics
In an effort to help physicians to manage VAP, the Tarragona
strategy – the basic principles of which are outlined in
Table 3 – has been proposed. Clearly, clinicians must be
aware of the common pathogens that are associated with
nosocomial pneumonia in their hospitals so that they can
avoid administering inadequate antibiotic therapy. Several
researchers have shown that inadequate antimicrobial
therapy is an important factor in the emergence of infections
due to resistant organisms [33,34]. Factors that contribute to
inadequate therapy for hospitalized patients include prior
antibiotic exposure, prolonged length of stay, prolonged
mechanical ventilation and presence of invasive devices.
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Figure 1
Different aetiologic patterns for multiresistant pathogens in different
institutions among patients who were mechanically ventilated for more
than 7 days and had prior antibiotic exposure. Acineto, Acinetobacter
baumannii; MRSA, methicillin-resistant Staphylococcus aureus; PA,
Pseudomonas aeruginosa; S.maltop, Stenotrophomonas maltophilia.263
Clinicians can improve antibiotic therapy, and therefore
outcome, in hospitalized patients by using empiric
combination antibiotic therapy based on individual patient
characteristics, the predominant bacterial flora and their local
antibiotic susceptibility profiles. Therapy can then be
narrowed once culture results are obtained. The effectiveness
of antibiotics to treat nosocomial infections can be preserved
by antibiotic cycling – that is, withdrawing an antibiotic or the
entire class from use and then reintroducing it at a later time
point [35,36].
The impact antibiotic therapy has on the outcome of VAP has
been assessed by several researchers [6,37–39], whose
work has become the basis for the concept that inadequate
antibacterial therapy is associated with increased mortality
rates. In a study conducted by Dupont and coworkers [40],
20 patients were given initial antibiotic therapy immediately
after bronchial sampling. If all of the significant organisms
were susceptible to at least one of the antibiotics used, then
initial therapy was considered to be appropriate. Antibiotic
therapy was adapted if necessary when the results of the
susceptibility testing were available (48–72 hours later).
Dupont and colleagues found that initial antibiotic therapy
was appropriate in only half of the patients, but when initial
antibiotic therapy was appropriate the patients experienced a
shorter stay (12 ± 11 days versus 20 ± 24 days) in the ICU.
Mechanical ventilation was also shorter for appropriately
treated  patients. The pathogens most associated with
inappropriate initial treatment were oxacillin-resistant S aureus
and P aeruginosa.
Successful treatment of patients with VAP remains difficult
and complex. Two factors appear to contribute to the
difficulty in selecting antibiotics for critically ill patients. First,
VAP is most likely to result from highly resistant organisms,
especially in those patients who were previously treated with
antibiotics [12]. Second, multiple organisms are frequently
cultured from the pulmonary secretions of ventilated patients
considered to have acquired pneumonia [32]. Thus, because
of the emergence of multiresistant, extended spectrum,
lactamase-producing, Gram-negative bacilli in many
institutions and the increasing role played by Gram-positive
bacteria such as MRSA, even a protocol combining
ceftazidime or imipenem and amikacin would not ensure
adequate coverage of all cases of VAP in these ICUs. Clearly,
there is a need for an agent with effective coverage of both
the Gram-positive and Gram-negative pathogens associated
with VAP.
The 1996 American Thoracic Society guidelines [16] make
recommendations for antimicrobial therapy for VAP based on
assessment of disease severity, the presence or absence of
risk factors for specific organisms and time of onset of the
pneumonia. However, one limitation of these guidelines is
that they do not take into account local susceptibilities; given
the range of bacteria that cause VAP and that their
susceptibilities vary widely among hospitals, selection of
initial antimicrobial therapy should be tailored to local
patterns of antimicrobial resistance [10,41].
Indeed, heavy use of third-generation cephalosporins and
aztreonam has been linked to the emergence of extended-
spectrum β-lactamases, with resulting drug resistance issues
[42]. Similarly, overuse of the fluoroquinolones, particularly
the older class members that have less activity against, for
example,  S pneumoniae, has led to the emergence of
fluoroquinolone-resistant pneumococci [43]. Moreover, a
study conducted by Trouillet and coworkers [33] comparing
patients who developed VAP caused by piperacillin-resistant
P aeruginosa with those who developed piperacillin-sensitive
P aeruginosa showed that previous fluoroquinolone use was
an independent risk factor for piperacillin-resistant P
aeruginosa VAP. Since 2000, two new classes of antibiotics
have been approved for the treatment of Gram-positive
bacteria: the oxazolidinones (e.g. linezolid) and the cyclic
lipopeptides (daptomycin). In US hospitals 50% of S aureus
isolates are methicillin resistant and 30% of enterococci are
vancomycin resistant, and so new investigational drugs are
extremely important. Even more recently introduced agents
such as linezolid, which is indicated for the treatment of
nosocomial pneumonia caused by MRSA [25,26], is
beginning to lose its effectiveness against staphylococci [44].
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Table 3
The Tarragona strategy
Point Details
1 Antibiotic therapy should be started immediately
2 Antibiotic choice can be targeted, in some cases, based on 
direct staining
3 The prescription should be modified in accordance with 
microbiologic findings
4 Prolonging antibiotic treatment does not prevent recurrence
5 Patients with chronic obstructive pulmonary disease or 
1 week of intubation should receive combination therapy 
because of the risk for ventilator-associated pneumonia 
caused by Pseudomonas aeruginosa
6 Methicillin-resistant Staphylococcus aureus is not 
anticipated in the absence of antibiotic exposure, whereas 
methicillin-sensitive S aureus should be strongly suspected 
in comatose patients
7 Therapy against yeast is not required, even in case of 
colonization with Candida spp.
8 Vancomycin administration for Gram-positive pneumonias is 
associated with very poor outcome
9 The specific choice of agent should avoid the regimen to 
which each patient has previously been exposed
10 Guidelines should be updated regularly and customized in 
accordance with local patterns
Modified from Sandiumenge and coworkers [41].264
The investigational new drug tigecycline, the first of a new
synthetic class of antibiotics called the glycylcyclines, has an
extended broad spectrum of activity that suggests it may be
an effective agent for the treatment of VAP [45]. Its MIC90
(concentration at which 90% of isolates are inhibited) values
have been shown to be significantly lower than those for
vancomycin, linezolid and quinupristin/dalfopristin against
clinically important Gram-positive and Gram-negative aerobic
bacteria, including S pneumoniae,  H influenzae,  M
catarrhalis, Neisseria gonorrhoeae, most Enterobacteriaceae
[including extended spectrum β-lactamase-producing strains],
and Enterococcus spp. and S aureus, including methicillin-
resistant strains [46]. Against P aeruginosa, tigecycline
exhibits modest activity (MIC90 ≥8 mg/l) [47]. Of particular
importance, tigecycline does not exhibit cross-resistance with
other classes of antimicrobial agents [46]. Clinical trials of
tigecycline in patients with VAP are awaited.
In addition to developing new antimicrobial agents, alternative
approaches to the management of VAP are also being
explored. For example, we know that different strains of P
aeruginosa have different expressions of virulence. Hauser
and coworkers [48] showed that secretion of type III proteins
is associated with worse outcomes for patients with VAP
caused by P aeruginosa and hypothesized that antibodies
targeted against these proteins could be effective in
prevention or therapy for VAP in such patients. Similarly,
Schulert and coworkers [49] have shown ExoU to be marker
of highly virulent strains of P aeruginosa, which again offers
the intriguing possibility of immunotherapy for P aeruginosa
induced VAP.
Finally, prevention of VAP should be our ultimate goal.
Measures to prevent VAP can target invasive devices, such
as ensuring adequate pressure in the endotracheal cuff,
removal of nasogastric and/or endotracheal tubes, subglottic
drainage, oral intubation, drainage of the condensate from the
ventilator circuits, and humidification with heat–moisture
exchangers. VAP prevention measures should also target the
potential pathogens and include hand washing, formal
infection control programmes, avoidance of unnecessary
antibiotics, and use of routine parenteral antibiotics in
comatose patients. Finally, to protect the patient from VAP,
health care providers should wear gowns and gloves, provide
adequate nutritional support, and limit the magnitude of
aspiration by placing patients in a semi-upright position [50].
Conclusion
VAP continues to present a major therapeutic challenge to
clinicians, particularly when patient management is
complicated by the presence of underlying conditions, which
are frequently present. The significant morbidity and mortality
associated with VAP require early, appropriate and adequate
antimicrobial therapy, ideally with an agent that has good
activity against both Gram-positive and Gram-negative
pathogens. Ready availability of local patterns of antimicrobial
resistance can help physicians in their decision making for
empirical therapy, which in turn should improve quality of care
and outcomes.
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